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Mitral valve 
repair in rheumatics: 
Is it still worthwhile?
Hospital, patients who had mitral valve repair lived longer than 
those who had valve replacement and freedom from reoperation 
was similar (Figure 1).(6) One further advantage of valvuloplasty is 
that, if and when reoperation is needed, it can usually be performed 
with mortality similar to that of primary surgery. 
These considerations usually do not pertain to the other form of 
rheumatic pathology, mitral stenosis. In these cases, when the valve 
is pliable, valvuloplasty can be performed with excellent long term 
results. Initially it was done by surgical closed commissurotomy, 
performed digitally or with a Tubbs dilator. Since then,  this proce-
dure has mostly been substituted by open mitral commissurotomy 
whereby the fused commissures can be visually opened with a 
scalpel, concomitantly intervening on the sub-mitral apparatus, if 
required. The closed procedure is however still performed in many 
developing countries with excellent results because of the advantage 
of low cost.
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COMMENTARY
Prosthetic valve replacement is plagued by several types of com-
plications which carry high mortality and morbidity. Among these, 
thromboembolism is the most feared. Thrombosis of mechanical 
prosthesis, especially, is a very lethal complication with a mortality 
rate of up to 60% and is more frequent in the mitral valve posi-
tion.(1) On the other hand, degeneration of bioprostheses limits 
durability and requires multiple reoperations, especially in younger 
patients. In addition, the mortality rate of reoperations is higher 
than that of primary surgery. It varies with the pathology, the 
condition of the patient and the experience of the surgical team, 
but ranges from 3% to 10% in most reports.(2,3) 
All these complications are even more frequent in rheumatic 
populations, characterised by a low mean age and poor socio-
economical conditions, which makes adherence to anticoagulation 
poor and follow-up difficult.(4,5) Hence, it is in these populations 
where the alternative of valve repair, especially of the mitral valve, 
would have the greatest benefit. Unfortunately, the results of mitral 
valvuloplasty in rheumatic mitral regurgitation are not as good as 
those observed in degenerative mitral regurgitation. But, how do 
these compare with those of prosthetic valve replacement in 
the same population? In my own experience at the Baragwanath 
Prosthetic valve replacement in young patients carries 
increased morbidity and mortality, even with recent types 
and models of prostheses. Fortunately, rheumatic mitral 
regurgitation in this young population group is amenable to 
repair, although the results are less favourable than those 
observed with other types of mitral valve disease and in older 
populations. A better knowledge of the pathology and 
evolution of repair  techniques  has  improved results. Hence 
mitral valve repair is still worthwhile, even in rheumatic 
pathology and,  the percentage of valves repaired, increases 
with the experience and the will of the surgeon to preserve 
the valve. Mitral valve replacement can only be justified 
when good repair is not feasible. It is vital that the surgeon 
has adequate experience which can only be gained by 
exposure to enough patients with this condition. Most of 
these patients are in developing countries and hampered by 
socio-economic conditions – which means 1st World sur-

















The surgical procedures were recently almost completely replaced 
by balloon mitral valvulotomy of which the main advantage is the 
avoidance of sternotomy and cardiopulmonary bypass. In my view, 
the results of this procedure are not as good as those of open 
mitral commissurotomy. In a series of 100 cases of open mitral 
commissurotomy performed in my department, systematically 
analysed by serial echocardiography, the mitral valve area was 
2.94cm2 immediately after surgery and 2.37cm2 at ten-year follow-
up.(7) These values are significantly superior to those commonly 
reported after balloon commissurotomy, which vary, in most 
series, from 2.0 to 2.2cm2.(8) In the past twenty years, we have 
performed open mitral commissurotomy in well over 1 500 cases. 
Obviously, not all valves are pliable and a number of them require 
valve replacement, but the surgery can still save many such valves. 
For the purpose of this article I will,  from now on restrict my 
comments to mitral regurgitation. One needs to distinguish be-
tween rheumatic mitral regurgitation presented in patients from 
developed countries in Europe and Asia and that of patients in 
developing countries. 
Patients in developed countries are usually older mostly in their 
fifties or sixties. They have a preponderance for annular dilation - 
most often with good leaflet tissue without prolapse - hence 
relatively easy to repair, provided that the mitral apparatus is not 
significantly fibrotic; and, as a result, have excellent long term 
outcomes. In a recent report, Wang et al. demonstrated a 6-year 
survival of approximately 80%.(9) 
By contrast, patients seen in developing countries are young mostly 
between 20 and 30 years of age. The diseased mitral valve is 
characterised by: Prolapse of the anterior leaflet; retraction of the 
posterior leaflet; annular dilatation; and, above all, relatively short 
leaflet tissue, thus rendering repair difficult. Moreover many patients 
present to surgery in the acute phase of rheumatic carditis.
tecHnIque oF MItrAl vAlve rePAIr                        
The mitral apparatus is a complex structure. It is composed of 
leaflets, chordae tendineae and papillary muscles, and even the 
ventricular and atrial walls play a role in its function. The nature of 
the rheumatic pathology of the mitral valve, with surgical implica-
tions, was largely not understood until the works of Carpentier in 
the seventies and eighties.(10) It has since clearly been demonstrated 
that in rheumatic regurgitation of the young patients there is most 
frequently elongation or rupture of the chordae tendineae of the 
anterior leaflet, causing prolapse in about 90% of the cases in my 
experience. By contrast, the chordae tendineae of the posterior 
leaflet are usually normal, but the leaflet may be retracted and quite 
frequently reduced to a very narrow band of tissue. Finally, annular 
dilation is present in approximately 95% of the cases. 
Because of this complex anatomic pathology of the valve, repair 
may be complex and obliges to at least correction of the leaflet 
prolapse and remodelling and/or size reduction of the annulus 
(Figure 2). With regards to the latter, it is now assumed that the 
annular dilation may not be just functional but also caused by the 
disease itself.(11) In fact, the annulus loses its capacity to contract 
and acquires an abnormal shape which needs to be restored to 
FIGure 1: Actuarial survival of young patients subjected to 
mitral valve surgery for rheumatic disease. Survival was better 
after valvuloplasty, as compared to replacement with a mechanical 
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normal. Finally, dilatation of the mitral annulus was always believed 
to occur in its posterior segment, the anterior segment being 
relatively protected from enlargement, but there is recent evidence 
that the anterior annulus can also dilate.(12)
Correction of the anterior leaflet prolapse, as initially proposed by 
Carpentier, is achieved by shortening of the chordae tendineae 
using one or more of several techniques, of which one of the most 
frequent was the opening of a trench in the corresponding head of 
the papillary muscle and burying the excess-length segment of 
the chordae.(10) This has proven to be one of weakest points of 
the valvuloplasty, especially in rheumatic cases, as the chordae 
tendineae continue to elongate due to progression of the disease. 
For this reason, I and others have for more than a decade now 
preferred the replacement/reinforcement of the chordae using 
artificial chordae made of GoreTex sutures (PTFE- polytetra-
fluorethylene). This method has proven much more durable and 
reproducible.(13) 
Treatment of the annular dilatation is most frequently done by 
implantation of an annuloplasty ring. Initially, there were two devices 
based on two different concepts: the rigid (Carpentier) and the 
flexible ring (Duran).(10,14) Both are closed rings conferring complete 
protection to the annulus. Theoretically, the flexible ring should be 
more physiologic as it would permit the normal variation of the 
shape of the annulus during the cardiac cycle, as was demonstrated 
in the laboratory by David.(15) However, this did not happen in 
practice, probably because of the pathological involvement of the 
annulus, as discussed above. Also, the ring becomes involved with 
fibrotic tissue which makes it less flexible. In my own experience, 
rheumatic disease requires the use of a completely rigid ring and 
the use of open rigid rings or bands, to protect the posterior 
annulus exclusively, has not yielded good results as has long ago 
been proven with annuloplasty consisting of sutures, as in the 
techniques of Reed and of Paneth.(16) I believe the complete rigid 
rings superior in the case of rheumatic disease in contrast to what 
may be the norm for non-rheumatic patients. 
Other techniques used in repairing rheumatic mitral valves include 
resection of secondary chordae of the posterior leaflet to decrease 
retraction and to improve the area of coaptation with the anterior 
leaflet. The Alfieri technique of edge-to-edge approximation may 
be used in extreme cases, but it was essentially developed for 
non-rheumatic valves with very large and mobile leaflets which 
can  tolerate  the double orifice physiology well.(17)
Importantly, the procedure must end with a perfectly competent 
valve. Even relatively minor degrees of residual regurgitation ob-
served on the operating table tend to be much greater in real 
physiological conditions. Hence the value of intra-operative trans-
oesophageal echocardiography, which is currently mandatory in 
any operation suite where these procedures are performed, is 
proved. Transoesophageal echocardiography has not only per-
mitted the immediate assessment of the results, allowing correc-
tion if necessary, but also helped surgeons to better understand 
the anatomy and physiology of the mitral valve.
MITRAl vAlvE REpAIR
FIGure 2: Repair of mitral valve regurgitation may be complex 
and often requires the association of several techniques involving 
the leaflet, the chordate tendineae, the papillary muscles and the 
annulus: a) chordal shortening; b) chordal transposition; c) leaflet 
resection; d) posterior leaflet chordal resection; e:)commissuro-


















results                                                                            
The techniques of mitral valve repair in rheumatic disease are, 
therefore, more complex and more difficult to master than in non-
rheumatic cases, especially in the case of isolated prolapse of the 
mid-scallop of the posterior leaflet (P2). The resulting learning 
curve(18) (Figure 3) has led many surgeons to give up early in this 
regard. Even some experienced repair surgeons have questioned 
the reparability of rheumatic valves in these young patient popula-
tion groups.(19)  
One of the main characteristics, impacting on the results of repair 
of rheumatic mitral regurgitation, is that the disease is progressive 
and, continues even after repair. The progression of the histo-
pathological rheumatic process inevitably leads to scarring with 
retraction of the leaflets and subvalvular apparatus which render 
the valve both stenotic and incompetent and eventually will lead 
to reoperation, most often to replace the valve (Figure 4). This 
progression of the disease, however, has significantly different 
consequences than those after failure of a prosthesis used for 
replacement. Only rarely, does the disease evolve so rapidly that it 
does not permit timely re-intervention. There is usually time for 
an adequate diagnosis and elective reoperation which, as indi- 
cated above, carries mortality similar to that of primary proce-
dures. Hence valve-related mortality is much lower than after valve 
replacement.(20)  
In  general, the survival free from cardiac or valve-related death 
is in excess of 90% after five years. In my own experience in 
the young rheumatic population, approximately 16% of the 
patients required reoperation after a mean follow-up of 6 years(21) 
(Figure 5). In these cases, most of the valves had mixed stenosis 
and regurgitation and valve failure was mostly associated with the 
shortening of chordae, need for commissurotomy and implanta-
tion of a Carpentier ring at the initial procedure. Freedom from 
valve-related mortality and from valve-related complications was 
96% and 80%, respectively, after 6 years of follow-up. The survival 
complication-free was significantly worse (72%) in patients aged 12 
years or less, as compared with that observed in patients older 
than 12 years (82%). 
These results, observed from my own follow-up of the patients, 
were later confirmed in the same study-population, in a study 
published by Skoularigis et al., which showed a global survival of 
76% and an event-free survival of 84% after a minimum of 9 years 
of follow-up.(22) Sixty per cent of the patients were free from 
reoperation, up to ten years after the operation. Similar results 
have also been reported from other parts of the world. In a paper 
published in 2000 by Pomerantzeff et al., from S. Paulo, Brazil, a 
FIGure 3: learning curve of mitral valve repair from my own 
experience. Shaded areas correspond to procedure failures, by 
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FIGure 4: Intraoperative photograph of a mitral valve, only a 
few years after valvuloplasty. Fibrotic changes led to both stenosis 
and regurgitation, requiring valve replacement.
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series of 201 patients with a mean age of 27 years operated on 
from March 1988 to December 1997 had an actual survival of 
93.9% after ten years and a survival free from reoperation of 
43.3% after the same follow-up.(23) In 2005, Talwar et al., from India, 
reported on 278 children, with a mean age 11.7 years, who were 
followed for a mean of 56.5 months. The actuarial, reoperation-free 
and event-free survivals were 95%, 92% and 56%, respectively.(24) 
recent exPerIence WItH rHeuMAtIc MItrAl 
reGurGItAtIon In coIMbrA 
It may be interesting to compare the experience described above 
with my recent experience with a different population group. 
During the period 1988 through 2009, 464 patients with rheu- 
matic mitral valve disease were operated on, of whom 418 had a 
valvuloplasty (91.1%). The remaining 9.9% required replacement. 
But it is important to note that most of the population group was 
constituted of patients with a mean age of 51 years, that is, patients 
who had rheumatic fever 3 or 4 decades ago, but a small per-
centage of patients coming from Africa were included. All patients 
younger than 20 years of age had their valve repaired. 
Comparatively, during this period, mitral valve repair was possible in 
94.9% of the patients with degenerative disease, in 72% of patients 
with infectious disease and in 93% of patients with ischaemic mitral 
regurgitation.
conclusIon                                                                     
Prosthetic valve replacement in young patients carries increased 
morbidity and mortality. Rheumatic mitral regurgitation in this 
young population group is amenable to repair, although the results 
are less favourable than those observed with other types of mitral 
valve disease, especially in older populations. However, a better 
knowledge of the pathology and evolution of the techniques of 
repair have led to improved results. The latter include avoidance of 
resection of anterior leaflet, use of PTFE chordae versus shortening 
of the chordae and use of pre-shaped rigid rings. Intra-operative 
transoesophageal echocardiography has proven most valuable. On 
the other hand, better anti-failure therapy, which is mandatory in all 
patients, even in the presence of an excellent functional result, has 
improved the outcome. Naturally, continued prophylaxis of rheu-
matic fever remains a very important component of the treatment 
of these patients. 
In conclusion, it is quite obvious that, even in rheumatic pathology, 
mitral valve repair is still worthwhile and that the percentage of 
valves repaired increases with the experience and the will of the 
surgeon to preserve the valve. In my view, mitral valve replacement 
is only justified when a good repair is not feasible, but the experi-
ence of the surgeon is absolutely vital. This can only be obtained by 
exposure to an adequate number of patients, which is usually made 
difficult by the political and economical situation in many under-
developed countries. Most countries still plagued by the rheumatic 
epidemic, including South Africa, had the total number of cardiac 
operations decreased in recent years and it has been claimed that 
the number of patients having valve surgery is currently half of 
what it was some years ago.(25,26) 
FIGure 5: Actuarial survival (open circles) and reoperation-free 
survival (squares) of 245 patients who had mitral valvuloplasty for 
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